NASDAQ:EOLS Evolus (EOLS) Stock Price, News & Analysis $15.70 +0.04 (+0.26%) (As of 11:07 AM ET) Add Compare Share Share Today's Range$15.51▼$15.9150-Day Range$10.45▼$15.6652-Week Range$7.44▼$15.91Volume94,231 shsAverage Volume580,167 shsMarket Capitalization$982.82 millionP/E RatioN/ADividend YieldN/APrice Target$21.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Evolus alerts: Email Address Evolus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside38.4% Upside$21.67 Price TargetShort InterestBearish8.05% of Shares Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews Sentiment0.54Based on 5 Articles This WeekInsider TradingSelling Shares$2.10 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.61) to $0.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.88 out of 5 starsMedical Sector181st out of 924 stocksPharmaceutical Preparations Industry67th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingEvolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvolus has only been the subject of 3 research reports in the past 90 days.Read more about Evolus' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.05% of the outstanding shares of Evolus have been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Evolus has recently decreased by 4.00%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEvolus has received a 40.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private dermatologist's appointments", "Private internist's appointments", and "Botulinum toxin" products. See details.Environmental SustainabilityThe Environmental Impact score for Evolus is -1.27. Previous Next 2.5 News and Social Media Coverage News SentimentEvolus has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Evolus this week, compared to 3 articles on an average week.Search Interest9 people have searched for EOLS on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Evolus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,103,392.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of Evolus is held by insiders.Percentage Held by Institutions90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Evolus' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($0.61) to $0.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -14.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -14.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvolus has a P/B Ratio of 50.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Evolus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. Click here to get details on this opportunity now. About Evolus Stock (NASDAQ:EOLS)Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Read More EOLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EOLS Stock News HeadlinesAugust 19 at 1:00 PM | nz.finance.yahoo.comEvolus, Inc. (EVL.F)August 18, 2024 | americanbankingnews.comEvolus (NASDAQ:EOLS) Trading 5.9% Higher August 22, 2024 | Stansberry Research (Ad)Millionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The Oracle of Omaha just sold HALF his stake – worth more than $75 billion in the iconic tech company.August 9, 2024 | msn.comEvolus, Inc. (EOLS): Is It One of Caligan Partners’ Top Holdings Now?August 5, 2024 | finance.yahoo.comEOLS Aug 2024 15.000 put (EOLS240816P00015000)August 3, 2024 | seekingalpha.comEvolus Continues To Make ProgressAugust 1, 2024 | markets.businessinsider.comEvolus Poised for Continued Growth with Strong Market Performance and Expanding Customer Base: Maintains Buy RatingJuly 31, 2024 | markets.businessinsider.comHere's what Wall Street expects from Evolus's earningsAugust 22, 2024 | Stansberry Research (Ad)Millionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The Oracle of Omaha just sold HALF his stake – worth more than $75 billion in the iconic tech company.July 31, 2024 | finance.yahoo.comEvolus Reports Second Quarter 2024 Results and Raises Full Year Revenue GuidanceJuly 31, 2024 | reuters.comEvolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rivalJuly 31, 2024 | investors.comEvolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters EarlyJuly 30, 2024 | finance.yahoo.comEvolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in AustraliaJuly 25, 2024 | finance.yahoo.comEvolus to Participate in the Canaccord Genuity 44th Annual Growth ConferenceJuly 22, 2024 | msn.comEvolus (EOLS) Is Capturing the Aesthetic Market with a Flagship ProductJuly 17, 2024 | businesswire.comEvolus to Report Second Quarter Financial Results on July 31, 2024June 24, 2024 | businesswire.comEvolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler ProductsJune 12, 2024 | businesswire.comEvolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in SpainSee More Headlines Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2024Today8/22/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EOLS CUSIPN/A CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$21.67 High Stock Price Target$27.00 Low Stock Price Target$16.00 Potential Upside/Downside+37.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,690,000.00 Net Margins-22.43% Pretax Margin-22.33% Return on EquityN/A Return on Assets-22.88% Debt Debt-to-Equity Ratio6.26 Current Ratio2.92 Quick Ratio2.96 Sales & Book Value Annual Sales$237.26 million Price / Sales4.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book50.77Miscellaneous Outstanding Shares62,600,000Free Float58,781,000Market Cap$985.32 million OptionableOptionable Beta1.29 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. David Moatazedi (Age 46)President, CEO & Director Comp: $1.75MMs. Sandra Beaver (Age 46)Chief Financial Officer Comp: $740.15kDr. Rui Avelar C.CFP (Age 62)Dip.SportMed, M.D., Chief Medical Officer and Head of Research & Development Comp: $823.19kMr. Nareg SagherianHead of Global Investor Relations & Corporate CommunicationsMr. Jeffrey J. PlumerGeneral CounselMr. Kurt KnabVice President of SalesMs. Tomoko Yamagishi-DresslerChief Marketing OfficerMs. Jessica NovakSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsAdamas PharmaceuticalsNASDAQ:ADMSArcellxNASDAQ:ACLXBiohavenNYSE:BHVNTG TherapeuticsNASDAQ:TGTXHUTCHMEDNASDAQ:HCMView All CompetitorsInsiders & InstitutionsStonepine Capital Management LLCSold 1,016,745 shares on 8/21/2024Ownership: 2.648%Algert Global LLCBought 19,368 shares on 8/16/2024Ownership: 0.031%Quarry LPBought 5,000 shares on 8/16/2024Ownership: 0.008%AQR Capital Management LLCBought 17,971 shares on 8/15/2024Ownership: 0.115%The Manufacturers Life Insurance Company Bought 5,808 shares on 8/15/2024Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions EOLS Stock Analysis - Frequently Asked Questions How have EOLS shares performed this year? Evolus' stock was trading at $10.53 at the start of the year. Since then, EOLS shares have increased by 48.7% and is now trading at $15.66. View the best growth stocks for 2024 here. How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) issued its quarterly earnings data on Wednesday, July, 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.02. The business had revenue of $66.91 million for the quarter, compared to analysts' expectations of $65.06 million. What is David Moatazedi's approval rating as Evolus' CEO? 1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Evolus IPO? Evolus (EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. Who are Evolus' major shareholders? Evolus' top institutional shareholders include Great Point Partners LLC (3.92%), Stonepine Capital Management LLC (2.65%), Assenagon Asset Management S.A. (1.51%) and Millennium Management LLC (1.44%). Insiders that own company stock include Alphaeon 1 Llc, Medytox Inc, David Moatazedi, Rui Avelar, Vikram Malik, Sandra Beaver, Lauren P Silvernail, David N Gill, Robert Hayman and Crystal Muilenburg. View institutional ownership trends. How do I buy shares of Evolus? Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Sorrento Therapeutics (SRNE). This page (NASDAQ:EOLS) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact ...Crypto 101 Media | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EOLS Stock Alerts